Iceland
Hepatitis B
Download HBV dataPrevalence of chronic HBV (HBsAg+)
National
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
0.89 (0.06 - 10.33) | 2015 | Modelled | WHO |
0.14 (0.04 - 0.56) | 2013 | Modelled | Schweitzer et al, 2015 |
0.65 (0.53 - 0.77) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
0.72 (0.59 - 0.84) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.72 (0.59 - 0.86) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.73 (0.60 - 0.87) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.73 (0.60 - 0.88) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.73 (0.60 - 0.88) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.73 (0.60 - 0.88) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.74 (0.60 - 0.87) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.74 (0.60 - 0.87) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.74 (0.60 - 0.88) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.74 (0.60 - 0.88) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.74 (0.61 - 0.87) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.75 (0.62 - 0.88) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.75 (0.62 - 0.88) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.75 (0.62 - 0.88) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.75 (0.62 - 0.89) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.76 (0.63 - 0.89) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.77 (0.63 - 0.90) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.77 (0.64 - 0.91) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.77 (0.63 - 0.92) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.78 (0.64 - 0.92) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.78 (0.64 - 0.92) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.78 (0.63 - 0.92) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.78 (0.63 - 0.92) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.78 (0.63 - 0.93) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.78 (0.63 - 0.94) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.79 (0.63 - 0.94) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.79 (0.63 - 0.95) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.79 (0.63 - 0.97) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.8 (0.63 - 0.98) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.71 (0.58 - 0.84) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
Children under-5 years
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
0.88 (0.06 - 10.46) | 2015 | Modelled | WHO |
0.3 (0.20 - 0.41) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
0.51 (0.34 - 0.72) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.52 (0.34 - 0.74) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.53 (0.33 - 0.76) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.54 (0.34 - 0.77) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.54 (0.34 - 0.77) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.54 (0.35 - 0.77) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.54 (0.36 - 0.77) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.54 (0.36 - 0.77) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.53 (0.36 - 0.77) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.53 (0.35 - 0.77) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.53 (0.36 - 0.76) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.53 (0.36 - 0.75) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.54 (0.37 - 0.74) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.54 (0.37 - 0.74) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.54 (0.37 - 0.74) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.55 (0.37 - 0.74) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.56 (0.38 - 0.76) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.57 (0.38 - 0.77) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.58 (0.38 - 0.79) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.58 (0.38 - 0.79) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.58 (0.39 - 0.79) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.58 (0.39 - 0.78) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.57 (0.39 - 0.77) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.57 (0.39 - 0.76) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.56 (0.38 - 0.76) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.56 (0.39 - 0.77) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.56 (0.39 - 0.78) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.57 (0.39 - 0.79) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.57 (0.38 - 0.81) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.57 (0.38 - 0.84) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.15 (0.05 - 0.40) | 2020 | Modelled | WHO |
Showing out of
Show more
Number of people living with chronic HBV
National
DownloadValue | Year | Type | Source |
---|---|---|---|
2,233 (1,827 - 2,641) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
2,298 (1,880 - 2,708) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,289 (1,874 - 2,678) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,275 (1,854 - 2,704) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,267 (1,859 - 2,704) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,257 (1,845 - 2,722) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,233 (1,826 - 2,670) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,213 (1,799 - 2,634) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,201 (1,787 - 2,620) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,196 (1,779 - 2,614) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,196 (1,776 - 2,610) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,194 (1,784 - 2,602) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,178 (1,782 - 2,566) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,147 (1,768 - 2,523) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,107 (1,741 - 2,482) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,070 (1,711 - 2,443) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,048 (1,701 - 2,419) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,041 (1,688 - 2,405) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,039 (1,687 - 2,408) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,032 (1,680 - 2,412) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,014 (1,650 - 2,391) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,991 (1,643 - 2,358) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,970 (1,621 - 2,336) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,954 (1,595 - 2,312) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,942 (1,573 - 2,296) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,930 (1,556 - 2,306) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,919 (1,550 - 2,294) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,908 (1,536 - 2,292) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,898 (1,518 - 2,291) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,888 (1,498 - 2,290) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,880 (1,469 - 2,309) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
HBV-related death rate
National
DownloadValue (per 100,000) | Year | Type | Source |
---|---|---|---|
1.32 (1.02 - 1.72) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
1.02 (0.78 - 1.31) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.04 (0.80 - 1.32) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.05 (0.81 - 1.34) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.06 (0.82 - 1.34) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.08 (0.84 - 1.38) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.11 (0.87 - 1.42) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.14 (0.88 - 1.45) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.14 (0.88 - 1.44) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.13 (0.88 - 1.45) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.12 (0.87 - 1.43) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.11 (0.86 - 1.40) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.11 (0.86 - 1.41) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.12 (0.86 - 1.41) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.11 (0.86 - 1.40) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.12 (0.86 - 1.41) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.14 (0.88 - 1.44) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.16 (0.89 - 1.47) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.16 (0.89 - 1.48) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.16 (0.89 - 1.47) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.19 (0.91 - 1.50) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.17 (0.90 - 1.48) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.21 (0.93 - 1.53) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.24 (0.95 - 1.58) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.25 (0.96 - 1.61) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.23 (0.94 - 1.57) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.28 (0.99 - 1.66) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.24 (0.95 - 1.59) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.26 (0.96 - 1.61) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.31 (1 - 1.70) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.32 (1.02 - 1.72) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
HBV-related deaths
National
Download
Showing out of
Show more
Percent of liver cancer deaths attributable to HBV
National
Download
Showing out of
Show more
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
No
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Year of HCV elimination goal
2025
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
% of substance use disorder facilities offering hepatitis treatment
Most (61-100%)
Hepatitis C
Download HCV dataPrevalence of chronic HCV (RNA+/cAg)
National
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
0.3 (0.20 - 0.40) | 2015 | Modelled | Blach et al, 2017 |
0.3 (0.30 - 0.40) | 2014 | Modelled | Olafsson S et al, 2018 |
0.68 (0.55 - 0.83) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.68 (0.55 - 0.83) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.67 (0.55 - 0.83) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.66 (0.54 - 0.81) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.64 (0.52 - 0.79) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.64 (0.52 - 0.79) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.64 (0.53 - 0.79) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.64 (0.53 - 0.79) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.65 (0.53 - 0.80) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.64 (0.52 - 0.79) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.64 (0.52 - 0.79) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.64 (0.52 - 0.79) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.64 (0.52 - 0.79) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.64 (0.52 - 0.78) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.63 (0.52 - 0.78) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.63 (0.52 - 0.78) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.63 (0.51 - 0.77) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.62 (0.51 - 0.77) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.62 (0.51 - 0.77) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.62 (0.50 - 0.76) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.61 (0.50 - 0.76) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.61 (0.50 - 0.75) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.61 (0.49 - 0.75) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.6 (0.49 - 0.75) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.6 (0.49 - 0.74) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.6 (0.49 - 0.74) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.6 (0.49 - 0.74) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.6 (0.49 - 0.74) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.6 (0.49 - 0.74) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.6 (0.49 - 0.75) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.63 (0.51 - 0.77) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
Showing out of
Show more
Prevalence of anti-HCV
People who inject drugs (PWID)
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
63 (59.80 - 66.20) | 1993 | Survey/reported | Love A et al, 1994 |
Number of people living with chronic HCV (RNA+/cAg)
National
DownloadValue | Year | Type | Source |
---|---|---|---|
1,000 (1,000 - 1,000) | 2015 | Modelled | Blach et al, 2017 |
1,415 (1,145 - 1,759) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,424 (1,158 - 1,773) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,435 (1,170 - 1,786) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,448 (1,180 - 1,794) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,462 (1,188 - 1,814) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,478 (1,203 - 1,836) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,498 (1,217 - 1,851) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,522 (1,237 - 1,882) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,549 (1,263 - 1,915) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,580 (1,285 - 1,944) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,609 (1,312 - 1,983) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,638 (1,335 - 2,019) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,665 (1,359 - 2,052) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,690 (1,380 - 2,084) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,718 (1,405 - 2,114) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,750 (1,427 - 2,156) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,790 (1,466 - 2,206) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,832 (1,502 - 2,264) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,870 (1,529 - 2,306) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,898 (1,541 - 2,336) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,915 (1,558 - 2,356) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,926 (1,570 - 2,372) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,931 (1,576 - 2,374) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,938 (1,579 - 2,384) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,955 (1,591 - 2,398) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,984 (1,613 - 2,442) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,052 (1,680 - 2,507) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,123 (1,741 - 2,607) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,162 (1,773 - 2,648) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,191 (1,789 - 2,674) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
2,168 (1,770 - 2,651) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
Showing out of
Show more
HCV-related death rate
National
DownloadValue (Deaths per 100,000) | Year | Type | Source |
---|---|---|---|
2.15 (1.66 - 2.70) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
1.3 (1.04 - 1.58) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.33 (1.06 - 1.61) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.36 (1.08 - 1.64) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.39 (1.11 - 1.66) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.44 (1.15 - 1.73) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.51 (1.21 - 1.82) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.56 (1.25 - 1.89) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.58 (1.27 - 1.92) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.6 (1.28 - 1.94) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.59 (1.27 - 1.92) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.57 (1.26 - 1.90) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.59 (1.28 - 1.93) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.61 (1.29 - 1.96) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.63 (1.30 - 1.99) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.65 (1.32 - 2.02) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.7 (1.34 - 2.08) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.73 (1.35 - 2.12) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.76 (1.38 - 2.16) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.77 (1.38 - 2.17) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.8 (1.41 - 2.21) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.85 (1.45 - 2.27) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.92 (1.50 - 2.36) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.99 (1.54 - 2.46) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.03 (1.58 - 2.52) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.99 (1.54 - 2.48) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.02 (1.55 - 2.54) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.11 (1.63 - 2.64) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.07 (1.60 - 2.58) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.16 (1.67 - 2.71) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.15 (1.66 - 2.70) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
HCV-related deaths
National
Download
Showing out of
Show more
Percent of liver cancer deaths attributable to HCV
National
Download
Showing out of
Show more
Number of persons treated for HCV
National
DownloadValue | Year | Type | Source |
---|---|---|---|
190 | 2017 | Survey/reported | ECDC, 2019 |
190 | 2017 | Survey/reported | The European Centre for Disease Prevention and Control, 2019 |
Showing out of
Show more
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
No
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Year of HCV elimination goal
2025
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
% of substance use disorder facilities offering hepatitis treatment
Most (61-100%)
Overview
HBV elimination goal
HCV elimination goal
Year of goal
2025
Prevalence (national)
Modelled
Survey/surveillance
No data available
No data available
Hepatitis related deaths (national)
Modelled
HBV
5
2019
(4 - 6)
IHME, GBD 2019 (accessed 2022)
Survey/surveillance
No data available
HBV chart
Modelled
HCV
7
2019
(6 - 9)
IHME, GBD 2019 (accessed 2022)
Survey/surveillance
No data available
HCV chart
Prevalence < 5
HBV
0.15
(%)
2020, latest modelled
(0.05 - 0.40(%))
WHO
Birth dose vaccination coverage (national)
Survey/surveillance
No data available
No. of syringes/PWID/year
Survey/surveillance
No data available
Eligible for HBV generic medicines
Eligible for HCV generic medicines